Dried blood spot analysis
A collaboration has been agreed between AB SCIEX and Alturas Analytics to accelerate the adoption of dried blood spot analysis for drug discovery and development.
A collaboration has been agreed between AB SCIEX and Alturas Analytics to accelerate the adoption of dried blood spot analysis for drug discovery and development. This analysis is designed to help pharmaceutical companies by simplifying the collection, storage and shipment of samples for pre-clinical and clinical studies in the drug development process. Scientists at Alturas are using QTRAP 5500 technology from AB SCIEX and micro-flow chromatography technology from Eksigent to further develop novel workflows based on microflow LC–MS for dried blood spot analysis and validate them to ensure that they meet Alturas’ quality assurance requirements. The new workflows are designed to require smaller sample volumes and provide sensitivity and low coefficient of variations.
“Dried blood spot analysis is a technique that can be used to solve complex bioanalytical problems,” said Shane Needham, laboratory director, Alturas Analytics. “Recent gains in sensitivity in analytical instrumentation have opened up remarkable new possibilities for pharmaceutical companies to take advantage of dried blood spot analysis.” Needham says that through their LC–MS instrumentation “AB SCIEX and Eksigent have helped to change the way we look at this type of analysis.“
For more information on these companies visit www.absciex.com and www.alturasanalytics.com
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
